Table 1. Selected Immunotherapy Trials in Bladder Cancer
Completed
Drug/Agent
Clinical trial
iden fier Study Stage of Disease
a
Atezolizumab
(MPDL3280A)
An -PD-L1
Cohort 1:
NCT02951767,
Cohort 2:
NCT02108652
Phase II Locally advanced or
metasta c – progressed
a er pla num-based
treatment
Pembrolizumab NCT02256436 Phase III vs. standard
of care chemotherapy
Locally advanced or
metasta c – progressed
a er pla num-based
treatment
Pembrolizumab NCT02335424 Phase II Non-cispla n eligible
pa ents
Ongoing
Drug/Agent
Clinical trial
iden fier Study Stage of Disease
a
Pembrolizumab NCT02625961 Phase II High risk NMIBC
unresponsive to BCG
therapy
Atezolizumab NCT02844816 Phase II NMIBC unresponsive to
BCG Therapy
Atezolizumab NCT02662309 Phase II preopera ve
MPDL3280A
Transi onal cell carcinoma
of the bladder
Atezolizumab
combina on with
cispla n and
gemcitabine
NCT02989584 Pilot safety,
neoadjuvant phase II
study
Metasta c bladder
cancer
Atezolizumab NCT02450331 Randomized phase III
atezolizumab as
adjuvant therapy vs.
observa on
High risk muscle-
invasive bladder cancer
Nivolumab NCT02632409 Randomized phase III
nivolumab as adjuvant
therapy vs. placebo
High risk muscle-
invasive bladder cancer
Maintenance
avelumab
NCT02603432 Phase III vs. best
suppor ve care alone
Locally advanced or
metasta c bladder
cancer that did
not progress a er
comple on of first-line
pla num-containing
chemotherapy
MEDI-4736
(an -PD-L1) ±
tremelimumab
(an -CTLA-4)
NCT02516241 Phase III, three arms:
MEDI-4736 ±
tremelimumab vs.
standard of care
chemotherapy
Unresectable stage IV
bladder cancer
a
As determined by ClinicalTrials.gov. Accessed Oct 4, 2017
